Jain Global’s Supernus Pharmaceuticals SUPN Stock Holding History

Jain Global’s Portfolio SUPN Stock Details SUPN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-123,291	Closed	-$6.13M	–	1632
2025 Q4	$6.13M	Buy	+123,291	New	+$5.99M	0.03%	397

Other funds holding SUPN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NAMI

Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jain Global's SUPN Position: Q1 2026 in Review

Jain Global sold out of Supernus Pharmaceuticals (SUPN) in Q1 2026, closing a stake of 123,291 shares — an estimated $6.13M sold.

Jain Global first reported a position in SUPN in Q4 2025 and held it in 1 quarter. The position peaked at $6.13M in Q4 2025. 327 funds tracked by Wall St. Rank hold SUPN as of Q1 2026.

Jain Global reported no remaining Supernus Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Jain Global sold 123,291 Supernus Pharmaceuticals shares in Q1 2026, an estimated $6.13M.
Jain Global first reported a position in Supernus Pharmaceuticals in Q4 2025 and held it in 1 quarter.
Jain Global's Supernus Pharmaceuticals position peaked at $6.13M in Q4 2025.
327 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q1 2026.

Based on Jain Global's 13F filing for Q1 2026, filed 15 May 2026.